

## **BRIEF SUMMARY OF THE TRANSPARENCY COMMITTEE OPINION**

### **DACRYOSERUM, DACUDOSSES, STERIDOSE (borax, boric acid), ophthalmic antiseptics**

#### **Moderate actual benefit in conjunctivitis**

#### **Main points**

- ▶ DACRYOSERUM, DACUDOSSES and STERIDOSE are antiseptic ophthalmic solutions that have Marketing Authorisation in the ocular lavage of cases of conjunctival irritation.
- ▶ These are supportive treatments in non-severe infectious conjunctivitis, with antibiotic treatment being restricted to severe forms.
- ▶ Due to the risk of contamination after opening a bottle of eye wash, single-dose containers are the most appropriate.

#### **Therapeutic use**

- The main symptoms of conjunctivitis are conjunctival hyperaemia, watering of the eyes, pruritus, and a foreign body sensation or burning sensation. The criteria for severe bacterial conjunctivitis are substantial purulent secretions, chemosis (conjunctival oedema), palpebral oedema, substantial watering of the eyes, even moderate loss of visual acuity, and photophobia.  
Antibiotics shorten the duration of symptoms in bacterial conjunctivitis, but their effect at 8 days is not significantly superior to placebo. Therefore, if the severity criteria are not met and there are no risk factors, antibiotics should not be used routinely. Treatment of bacterial conjunctivitis should primarily consist of ocular lavage with saline solution combined with an antiseptic, antibiotic treatment being restricted to severe forms.
- **Role of the medicinal product in the therapeutic strategy**  
This proprietary medicinal product is a supportive treatment in non-severe infectious conjunctivitis, with antibiotic treatment being restricted to severe forms. It has no role in the treatment of other types of conjunctivitis.

#### **Benefit of the medicinal product**

- The actual benefit\* of DACRYOSERUM, DACUDOSSES and STERIDOSE is moderate.
- Recommends continued inclusion on the list of reimbursable products for supply by pharmacists and for hospital use.



HAUTE AUTORITÉ DE SANTÉ

This document was created on the basis of the Transparency Committee Opinion of 04 November 2015 (CT-10750, CT 10788, CT-11213) and is available at [www.has-sante.fr](http://www.has-sante.fr)

<sup>i\*</sup> The actual benefit (AB) of a proprietary medicinal product describes its benefit primarily in terms of its clinical efficacy and the seriousness of the condition being treated. The HAS Transparency Committee assesses the AB, which can be substantial, moderate, low or insufficient for reimbursement for hospital use.